JP6764856B2 - Stomach volume reducer - Google Patents
Stomach volume reducer Download PDFInfo
- Publication number
- JP6764856B2 JP6764856B2 JP2017506513A JP2017506513A JP6764856B2 JP 6764856 B2 JP6764856 B2 JP 6764856B2 JP 2017506513 A JP2017506513 A JP 2017506513A JP 2017506513 A JP2017506513 A JP 2017506513A JP 6764856 B2 JP6764856 B2 JP 6764856B2
- Authority
- JP
- Japan
- Prior art keywords
- glutamine
- phenylalanine
- methionine
- present
- gastric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002784 stomach Anatomy 0.000 title claims description 39
- 239000003638 chemical reducing agent Substances 0.000 title claims description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 77
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 70
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 69
- 229930182817 methionine Natural products 0.000 claims description 57
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 56
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 56
- 230000002496 gastric effect Effects 0.000 claims description 54
- 239000003795 chemical substances by application Substances 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 42
- 239000004480 active ingredient Substances 0.000 claims description 19
- 230000001603 reducing effect Effects 0.000 claims description 18
- 230000000638 stimulation Effects 0.000 claims description 10
- 230000037406 food intake Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 230000030136 gastric emptying Effects 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 229960002743 glutamine Drugs 0.000 description 68
- 229960004452 methionine Drugs 0.000 description 63
- 229960005190 phenylalanine Drugs 0.000 description 57
- 235000013305 food Nutrition 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 36
- 238000000034 method Methods 0.000 description 25
- 208000008589 Obesity Diseases 0.000 description 22
- 235000020824 obesity Nutrition 0.000 description 21
- 239000013589 supplement Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 16
- 229930182816 L-glutamine Natural products 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000003044 adaptive effect Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229930195722 L-methionine Natural products 0.000 description 10
- 239000000654 additive Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000000996 additive effect Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 102000011632 Caseins Human genes 0.000 description 7
- 108010076119 Caseins Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- -1 acidulants Substances 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 235000021119 whey protein Nutrition 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 206010020710 Hyperphagia Diseases 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000007681 bariatric surgery Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- UJOYFRCOTPUKAK-MRVPVSSYSA-N (R)-3-ammonio-3-phenylpropanoate Chemical compound OC(=O)C[C@@H](N)C1=CC=CC=C1 UJOYFRCOTPUKAK-MRVPVSSYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Chemical group CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Chemical group 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Chemical group 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000086 alane Inorganic materials 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001746 carotenes Chemical group 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000019543 dairy drink Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011306 frozen processed food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Chemical group CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Chemical group O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Chemical group 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Chemical group 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本願は、先行する日本国出願である特願２０１５−５０５８３（出願日：２０１５年３月１３日）の優先権の利益を享受するものであり、その開示内容全体は引用することにより本明細書の一部とされる。 The present application enjoys the benefit of the priority of Japanese Patent Application No. 2015-50583 (filed on March 13, 2015), which is a prior application in Japan, and the entire disclosure thereof is hereby cited by reference. Be part of.
本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有する胃容量の減少剤に関する。 The present invention relates to a gastric volume reducing agent containing one or more selected from glutamine, methionine and phenylalanine as an active ingredient.
生活習慣病は、遺伝による要因（もともと、その病気になりやすい体質など）と、生活習慣による要因（食べすぎや飲みすぎ、運動不足、喫煙など）により、発病・進行する病気である。ここで、生活習慣病としては、高血圧、高脂血症、糖尿病などが挙げられ、これらの重要な要因として、食べすぎや飲みすぎ、運動不足などに伴う、肥満が挙げられる。 Lifestyle-related diseases are diseases that develop or progress due to genetic factors (originally, predisposition to the disease, etc.) and lifestyle-related factors (overeating, drinking too much, lack of exercise, smoking, etc.). Here, lifestyle-related diseases include hypertension, hyperlipidemia, diabetes, and the like, and important factors thereof include obesity due to overeating, drinking too much, lack of exercise, and the like.
肥満の治療法として、食事療法（ダイエット）や運動療法が知られているが、これらの療法では、なかなか十分に有効な効果が見られないのが実情である。 Diet and exercise therapies are known as treatments for obesity, but the reality is that these therapies do not have sufficiently effective effects.
最近では、約８００人を試験対象とした臨床研究により、肥満の治療方法として、食事療法や運動療法に比べて、外科手術では、有効な効果が見られることが示されている。具体的には、肥満の人達を被験者とした１１項目の臨床研究を分析したところ、外科手術を伴わない減量法（食事療法、運動療法、行動療法、投薬など）に比べて、胃バンディング（緊縛）、胃バイパス、胃切除などの外科手術では、２年間で体重が平均して２６キロも多く減少したことが示されている（非特許文献１）。 Recently, a clinical study of about 800 subjects has shown that surgery is more effective than diet and exercise as a treatment for obesity. Specifically, when we analyzed 11 clinical studies of obese people as subjects, we found that gastric banding (binding) compared to weight loss methods without surgery (diet therapy, exercise therapy, behavior therapy, medication, etc.) ), Surgery such as gastric bypass and gastric resection have been shown to lose an average of 26 kg in two years (Non-Patent Document 1).
また、外科手術以外の方法では、食物繊維が水分を吸収して、胃に留まることにより、膨満感が得られる結果として、食欲を抑える方法などが報告されている（例えば、特許文献１）。 Further, in methods other than surgery, a method of suppressing appetite as a result of obtaining a feeling of fullness by absorbing water by dietary fiber and staying in the stomach has been reported (for example, Patent Document 1).
本発明者らは、胃に対して非侵襲的なスクリーニング方法を用いて、胃容量を減少させる素材についてスクリーニングを行ったところ、食経験のある主要なアミノ酸である、グルタミン、メチオニンおよびフェニルアラニンが胃容量の減少に有効であることを見出した。 We screened for materials that reduce gastric volume using a non-invasive screening method for the stomach, and found that the major amino acids with dietary experience, glutamine, methionine, and phenylalanine, were found in the stomach. It was found to be effective in reducing capacity.
具体的には、ラットを用いたインビボ（in vivo）試験において、麻酔下で強制的に動物の胃内にバルーンを留置して、動物の胃の内圧を高めることを特徴とするスクリーニング方法を用いた。この試験系は胃に対して非侵襲的であるため、胃の生理的状況により近いといえる。 Specifically, in an in vivo test using rats, a screening method characterized by forcibly placing a balloon in the stomach of an animal under anesthesia to increase the internal pressure of the stomach of the animal is used. There was. Since this test system is non-invasive to the stomach, it can be said to be closer to the physiological condition of the stomach.
本発明者らは、この試験系を用いて、アミノ酸を投与して動物に胃の伸展刺激を与えたときの適応弛緩をモニターしたところ、グルタミン、メチオニンおよびフェニルアラニンが、胃の伸展刺激に適応した（胃の伸展刺激を与えたときに）胃底部および／または胃体上部の弛緩を抑制することを見出した。本発明は上記知見に基づくものである。 Using this test system, we monitored the adaptive relaxation when amino acids were administered to stimulate gastric extension in animals, and glutamine, methionine, and phenylalanine adapted to the stimulation of gastric extension. It was found to suppress the relaxation of the fundus and / or the upper body of the stomach (when given a gastric extension stimulus). The present invention is based on the above findings.
本発明は、安全で長期摂取が可能な胃容量の減少剤の提供を目的とする。 An object of the present invention is to provide a gastric volume reducing agent that is safe and can be ingested for a long period of time.
また、本発明によれば以下の発明が提供される。
［１］グルタミン、メチオニンおよびフェニルアラニンからなる群から選択される１種または２種以上のアミノ酸を有効成分として含有する、胃容量の減少剤。
［２］胃の伸展刺激に適応した胃底部および／または胃体上部の弛緩を抑制する、上記［１］に記載の剤。
［３］胃排出を促進しないことを特徴とする、上記［１］または［２］に記載の剤。
［４］グルタミン、メチオニンおよびフェニルアラニンからなる群から選択される１種または２種以上のアミノ酸を有効成分として含有する、肥満の予防、治療および／または改善剤。
［５］ヒトの１日当たりのアミノ酸の摂取量または投与量がアミノ酸の固形分換算で０．２〜５ｇとなるよう配合されてなる、上記［１］〜［４］のいずれかに記載の剤。
［６］１回の摂取量または投与量当たりの包装単位形態からなる、上記［１］〜［５］のいずれかに記載の剤。
［７］グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上のアミノ酸を経口摂取させることを含んでなる、胃容量を減少させる方法。
［８］胃容量の減少剤の製造のための、グルタミン、メチオニンおよびフェニルアラニンからなる群から選択される１種または２種以上のアミノ酸の使用。
［９］グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上のアミノ酸を、それを必要とするヒトを含む哺乳類に投与することを含んでなる、肥満の予防、治療および／または改善方法。
［１０］肥満の予防、治療および／または改善剤の製造のための、グルタミン、メチオニンおよびフェニルアラニンからなる群から選択される１種または２種以上のアミノ酸の使用。Further, according to the present invention, the following inventions are provided.
[1] An agent for reducing gastric volume, which comprises one or more amino acids selected from the group consisting of glutamine, methionine and phenylalanine as an active ingredient.
[2] The agent according to the above [1], which suppresses relaxation of the fundus and / or the upper body of the stomach adapted to the stimulation of gastric extension.
[3] The agent according to the above [1] or [2], which does not promote gastric emptying.
[4] An agent for preventing, treating and / or ameliorating obesity, which comprises one or more amino acids selected from the group consisting of glutamine, methionine and phenylalanine as an active ingredient.
[5] The agent according to any one of the above [1] to [4], which is formulated so that the daily intake or dose of amino acids in humans is 0.2 to 5 g in terms of solid content of amino acids. ..
[6] The agent according to any one of the above [1] to [5], which comprises a single ingestion amount or a packaging unit form per dose.
[7] A method for reducing gastric volume, which comprises ingesting one or more amino acids selected from glutamine, methionine and phenylalanine.
[8] Use of one or more amino acids selected from the group consisting of glutamine, methionine and phenylalanine for the production of gastric volume reducing agents.
[9] A method for preventing, treating and / or ameliorating obesity, which comprises administering one or more amino acids selected from glutamine, methionine and phenylalanine to mammals including humans who need them. ..
[10] Use of one or more amino acids selected from the group consisting of glutamine, methionine and phenylalanine for the prevention, treatment and / or production of ameliorating agents for obesity.
本発明によれば、安全で長期摂取が可能な胃容量の減少剤を提供することができる。 According to the present invention, it is possible to provide a gastric volume reducing agent that is safe and can be ingested for a long period of time.
本発明者らは、非ヒト哺乳動物に非侵襲的に胃内バルーンを留置することを特徴とする、新たなスクリーニング方法を見出した。このスクリーニング方法は、後述の試験（例１）で示すように、ラットなどの非ヒト哺乳動物を用いたインビボ試験において、麻酔下で強制的に動物の胃内にバルーンを留置し、被検試料の投与の後に動物の胃の内圧を高めて胃に伸展刺激を与え、Ａｄａｐｔｉｖｅ ｒｅｌａｘａｔｉｏｎ（適応弛緩）をモニターすることで、胃底部の弛緩を評価することを特徴とする。従来のスクリーニング方法では、非ヒト哺乳動物を開腹し、胃を切開してバルーンを留置していたため、胃に対して侵襲的であり、生理的状況を再現しているとは言い難かった。それに対し、このスクリーニング方法は胃に対して非侵襲的であるため、胃の生理的状況により近い試験系であるといえる。ここで、「適応弛緩」（適応性弛緩）とは、食物が胃に入ったときに胃の内圧の増加に応答して胃底部が膨張する胃の反射作用をいう。 The present inventors have found a novel screening method characterized by non-invasive placement of a gastric balloon in a non-human mammal. In this screening method, as shown in the test described later (Example 1), in an in vivo test using a non-human mammal such as a rat, a balloon is forcibly placed in the stomach of the animal under anesthesia and a test sample is used. It is characterized in that the relaxation of the fundus is evaluated by increasing the internal pressure of the stomach of the animal after administration of the animal to stimulate the stomach to stretch and monitoring Adaptive relaxation (adaptive relaxation). In the conventional screening method, a non-human mammal was opened, the stomach was incised, and a balloon was placed, so that it was invasive to the stomach and it was difficult to say that it reproduced the physiological situation. On the other hand, since this screening method is non-invasive to the stomach, it can be said that it is a test system closer to the physiological condition of the stomach. Here, "adaptive relaxation" (adaptive relaxation) refers to the reflex action of the stomach in which the fundus expands in response to an increase in the internal pressure of the stomach when food enters the stomach.
本発明者らは、後述の試験（例１）で２０種類のアミノ酸をスクリーニングし、３種のアミノ酸（グルタミン（Ｇｌｎ）、メチオニン（Ｍｅｔ）およびフェニルアラニン（Ｐｈｅ））が、胃の伸展刺激に適応した胃底部（Ｆｕｎｄｕｓ）および／または胃体上部（Ｆｏｒｅｓｔｏｍａｃｈ）の弛緩を抑制することを見出した。つまり、本発明者らは、グルタミン、メチオニンおよびフェニルアラニンが、胃容量を可逆的に減少させることを見出した。 The present inventors screened 20 kinds of amino acids in the test described later (Example 1), and 3 kinds of amino acids (glutamine (Gln), methionine (Met) and phenylalanine (Phe)) were adapted to stimulate the extension of the stomach. It has been found that it suppresses the relaxation of the fundus and / or the upper body of the stomach (Forestomach). That is, we have found that glutamine, methionine and phenylalanine reversibly reduce gastric volume.
本発明の胃容量の減少剤は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有する。あるいは本発明の剤の態様として、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上のみを有効成分として含有する剤であってもよく、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上のみを含有する剤を例示することもできる。 The gastric volume reducing agent of the present invention contains one or more selected from glutamine, methionine and phenylalanine as an active ingredient. Alternatively, as an embodiment of the agent of the present invention, it may be an agent containing only one or more selected from glutamine, methionine and phenylalanine as an active ingredient, and one selected from glutamine, methionine and phenylalanine or It is also possible to exemplify an agent containing only two or more kinds.
本発明において「胃容量の減少」は、胃の伸展刺激に適応した胃底部および／または胃体上部の弛緩を指標して評価することができる（例１参照）。例えば、例１のスクリーニング系において、対照試料投与時の適応弛緩による胃の拡張と比較して胃の拡張が抑制された場合に、胃容量を減少させたと判断することができる。具体的には、例１のスクリーニング系において、適応弛緩による胃の増加体積が、対照試料投与時の増加体積の８０％以下（好ましくは７０％以下、より好ましくは６０％以下）であった場合に、胃容量を減少させたと判断することができる。 In the present invention, "decrease in gastric volume" can be evaluated by indexing the relaxation of the fundus and / or the upper body of the stomach adapted to the stimulation of gastric extension (see Example 1). For example, in the screening system of Example 1, it can be determined that the gastric volume is reduced when the gastric distension is suppressed as compared with the gastric distension due to adaptive relaxation at the time of administration of the control sample. Specifically, in the screening system of Example 1, when the increased volume of the stomach due to adaptive relaxation was 80% or less (preferably 70% or less, more preferably 60% or less) of the increased volume at the time of administration of the control sample. In addition, it can be judged that the gastric capacity has been reduced.
本発明の剤は好ましくは胃の弛緩を抑制するために用いることができ、より好ましくは、胃の伸展刺激に適応した胃底部および／または胃体上部の弛緩を抑制するために用いることができる。また別の観点から、本発明の剤は胃排出を促進せずに（胃排出を抑制しつつ）胃容量を減少させるために用いることができる。 The agent of the present invention can preferably be used to suppress the relaxation of the stomach, and more preferably to suppress the relaxation of the fundus and / or the upper body of the stomach adapted to the stimulation of gastric extension. it can. From another point of view, the agent of the present invention can be used to reduce gastric volume without promoting gastric emptying (while suppressing gastric emptying).
グルタミン（Ｇｌｕｔａｍｉｎｅ）は、必須アミノ酸の１つであり、それには、Ｄ体とＬ体が存在する。Ｌ−グルタミンのＣａｓ Ｎｏ．は、５６−８５−９であり、その別名は、（Ｓ）−２−アミノ−４−カルバモイルブタン酸、グルミン、γ−グルタミン、Ｌ−（＋）−グルタミンである。グルタミンの略号として、Ｇｌｎ、Ｑを用いる場合もある。グルタミンは、蟻酸に溶けやすく、水にやや溶けやすく、エタノールにほとんど溶けない（第十六改正日本薬局方）。グルタミンは、小麦たんぱく、カゼイン、大豆、豚肉など様々な素材や食品に含まれていることが知られている。 Glutamine is one of the essential amino acids, in which D-form and L-form are present. L-Glutamine Cas No. Is 56-85-9, and its aliases are (S) -2-amino-4-carbamoylbutanoic acid, glutamine, γ-glutamine, and L- (+)-glutamine. Gln and Q may be used as abbreviations for glutamine. Glutamine is freely soluble in formic acid, slightly soluble in water, and practically insoluble in ethanol (16th revised Japanese Pharmacopoeia). Glutamine is known to be contained in various ingredients and foods such as wheat protein, casein, soybeans, and pork.
メチオニン（Ｍｅｔｈｉｏｎｉｎｅ）は、必須アミノ酸の１つであり、それには、Ｄ体とＬ体が存在する。Ｌ−メチオニンのＣａｓ Ｎｏ．は、６３−６８−３であり、その別名は、（Ｓ）−４−（メチルチオ）−２−アミノ酪酸、（Ｓ）−２−アミノ−４−（メチルチオ）ブタン酸、（Ｓ）−３−フェニル−２−アミノプロピオン酸、Ｌ−（−）−メチオニンである。メチオニンの略号として、Ｍｅｔ、Ｍを用いる場合もある。メチオニンは、蟻酸に溶けやすく、水にやや溶けやすく、希塩酸に溶け、エタノールには極めて溶けにくい（第十六改正日本薬局方）。メチオニンは、カゼイン、かつお、大豆など様々な素材や食品に含まれていることが知られている。 Methionine is one of the essential amino acids, in which D-form and L-form are present. L-Methionine Cas No. Is 63-68-3, and its aliases are (S) -4- (methylthio) -2-aminobutyric acid, (S) -2-amino-4- (methylthio) butanoic acid, (S) -3. -Phenyl-2-aminopropionic acid, L- (-)-methionine. Met and M may be used as abbreviations for methionine. Methionine is freely soluble in formic acid, slightly soluble in water, soluble in dilute hydrochloric acid, and extremely sparingly soluble in ethanol (16th revised Japanese Pharmacopoeia). Methionine is known to be contained in various materials and foods such as casein, bonito and soybeans.
フェニルアラニン（Ｐｈｅｎｙｌａｌａｎｉｎｅ）は、必須アミノ酸の１つであり、それには、Ｄ体とＬ体が存在する。Ｌ−フェニルアラニンのＣａｓ Ｎｏ．は、６３−９１−２であり、その別名は、（Ｓ）−α−アミノベンゼンプロパン酸、（２Ｓ）−２−アミノ−３−フェニルプロパン酸、（Ｓ）−３−フェニル−２−アミノプロピオン酸、Ｌ−β−フェニルアラニン、Ｌ−（−）−フェニルアラニンである。フェニルアラニンの略号として、Ｐｈｅ、Ｆを用いる場合もある。フェニルアラニンは、蟻酸に溶けやすく、水にやや溶けにくく、希塩酸に溶け、エタノールにはほとんど溶けない（第十六改正日本薬局方）。フェニルアラニンは、多種のタンパク質などの様々な素材や食品に含まれていることが知られている。 Phenylalanine is one of the essential amino acids, in which D and L forms are present. L-Phenylalanine Cas No. Is 63-91-2, and its aliases are (S) -α-aminobenzenepropanoic acid, (2S) -2-amino-3-phenylpropanoic acid, and (S) -3-phenyl-2-amino. Propionic acid, L-β-phenylalanine, L- (-)-phenylalanine. Ph, F may be used as an abbreviation for phenylalanine. Phenylalanine is easily soluble in formic acid, sparingly soluble in water, soluble in dilute hydrochloric acid, and practically insoluble in ethanol (16th revised Japanese Pharmacopoeia). Phenylalanine is known to be contained in various materials and foods such as various proteins.
本発明において、グルタミン、メチオニンおよびフェニルアラニンは、フリーベースや水和物であってもよく、また、有機酸（酢酸、酒石酸、脂肪酸など）、有機塩基、無機酸（塩酸、臭化水素酸、硝酸、硫酸、過塩素酸など）、無機塩基（カリウム、ナトリウム、亜鉛など）と塩を形成していても構わない。そして、グルタミン、メチオニンおよびフェニルアラニンには、Ｄ体とＬ体のいずれを用いてもよいが、Ｌ体 を用いることが好ましい。 In the present invention, glutamine, methionine and phenylalanine may be free bases or hydrates, and may be organic acids (acetic acid, tartaric acid, fatty acids, etc.), organic bases, inorganic acids (hydrochloric acid, hydrobromic acid, sulfuric acid, etc.). , Sulfuric acid, perchloric acid, etc.), and inorganic bases (potassium, sodium, zinc, etc.) may form salts. As glutamine, methionine and phenylalanine, either D-form or L-form may be used, but it is preferable to use L-form.
本発明において、グルタミン、メチオニンおよびフェニルアラニンは、グルタミン、メチオニン、フェニルアラニンを多く含む素材や食品などから、搾汁、濃縮、精製、結晶化または各種の溶媒で抽出するなどして得ることができる。各種の溶媒として、水や通常に用いられる溶媒、例えば、アルコール類、炭化水素類、有機酸、有機塩基、無機酸、無機塩基、超臨界流体等を単独で、あるいは複数を組み合わせて用いることが可能である。また、微生物で生産したものを用いることも可能である。そして、化学的に合成されたものを用いることも可能である。 In the present invention, glutamine, methionine and phenylalanine can be obtained from materials and foods rich in glutamine, methionine and phenylalanine by squeezing, concentrating, purifying, crystallization or extracting with various solvents. As various solvents, water or commonly used solvents such as alcohols, hydrocarbons, organic acids, organic bases, inorganic acids, inorganic bases, supercritical fluids, etc. may be used alone or in combination of two or more. It is possible. It is also possible to use those produced by microorganisms. Then, it is also possible to use a chemically synthesized one.
本発明の剤は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有してなり、食品衛生上または医薬上で許容可能な他の添加成分とを組み合わせた組成物として構成してもよい。したがって、本発明の剤は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有し、さらに、食品衛生上または医薬上で許容可能な他の添加成分とを含有する、胃容量を減少させるための組成物、あるいは後記疾患や症状（特に肥満）の予防、治療および／または改善のための組成物として提供される。この場合、上記組成物は胃容量を減少させるための有効量、あるいは、後記疾患や症状（特に肥満）の予防、治療および／または改善のための有効量、のグルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上のアミノ酸を含んでなるものである。 The agent of the present invention contains one or more selected from glutamine, methionine and phenylalanine as an active ingredient, and is a composition in combination with other additive ingredients that are acceptable for food hygiene or pharmaceutically acceptable. It may be configured as. Therefore, the agent of the present invention contains one or more selected from glutamine, methionine and phenylalanine as an active ingredient, and further contains other additive ingredients that are acceptable for food hygiene or pharmaceutically acceptable. , A composition for reducing gastric volume, or a composition for the prevention, treatment and / or amelioration of diseases and symptoms (particularly obesity) described below. In this case, the composition is selected from glutamine, methionine and phenylalanine, which are effective amounts for reducing gastric volume or for preventing, treating and / or ameliorating diseases and symptoms (particularly obesity) described below. It contains one or more amino acids.
本発明において、他の添加成分は、特に限定されず、本発明の剤の効果を促進するものや阻害しないものを優先的に用いることができる。本発明の他の添加成分として、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、矯臭剤、溶解補助剤、懸濁剤またはコーティング剤などの製剤化補助剤、ビタミン、ミネラル、有機酸、糖類、ペプチド類、甘味料、酸味料、乳化剤または香料などが挙げられる。 In the present invention, the other additive components are not particularly limited, and those that promote or do not inhibit the effect of the agent of the present invention can be preferentially used. Other additives of the invention include, for example, excipients, binders, disintegrants, lubricants, fragrances, solubilizers, suspending or coating agents and other formulation aids, vitamins, minerals, organics. Examples include acids, sugars, peptides, sweeteners, acidulants, emulsifiers or flavors.
本発明において、実際の形態は、特に限定されず、本発明の剤の効果を促進するものや阻害しないものを優先的に用いることができる。本発明の剤の実際の形態として、例えば、錠剤（タブレット）、カプセル剤、顆粒剤、散剤、シロップ剤、水剤、懸濁剤、ドリンク剤またはサプリメントが挙げられる。 In the present invention, the actual form is not particularly limited, and those that promote or do not inhibit the effect of the agent of the present invention can be preferentially used. Practical forms of the agents of the present invention include, for example, tablets, capsules, granules, powders, syrups, liquids, suspensions, drinks or supplements.
本発明において、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上の配合量は、剤型、症状、体重、用途などによって異なるため、特に限定されないが、あえて挙げるなら、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上のアミノ酸（固形分換算）で、下限値を０．１％、０．２％、０．５％、０．８％、１％、２％、５％、８％、上限値を１００％、９０％、８０％、７０％、６０％、５０％、４０％、３０％、２０％または１５％の配合量に設定することができる。本発明において、「％」は、特に記載がない限り「ｗ／ｗ％」である。 In the present invention, the blending amount of one or more selected from glutamine, methionine and phenylalanine varies depending on the dosage form, symptoms, body weight, use and the like, and is not particularly limited. However, if mentioned, glutamine, methionine and One or more amino acids selected from phenylalanine (in terms of solid content) with lower limit values of 0.1%, 0.2%, 0.5%, 0.8%, 1%, 2%, 5 %, 8%, and the upper limit can be set to 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 15%. In the present invention, "%" is "w / w%" unless otherwise specified.
本発明において、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上のアミノ酸の一日当たりの摂取量および投与量は、年齢、症状、体重、用途などによって異なるため、特に限定されないが、あえて挙げるなら、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上のアミノ酸（固形分換算）で、下限値を０．２ｇ、０．３ｇ、０．４ｇ、０．５ｇ、０．６ｇ、または０．９ｇ、上限値を５ｇ、４ｇ、３ｇ、２．５ｇ、２ｇ、または１．５ｇ、に設定して摂取あるいは投与する例が挙げられる。より具体的には、胃容量を減少させるための、あるいは、後記疾患や症状（特に肥満）の予防、治療および／または改善のための、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上のアミノ酸（固形分換算）のヒト一日当たりの摂取量および投与量は、０．２〜５ｇとすることができ、好ましくは０．３〜４．０ｇ、より好ましくは０．７〜２．０ｇ、特に好ましくは０．９〜１．５ｇである。 In the present invention, the daily intake and dose of one or more amino acids selected from glutamine, methionine and phenylalanine vary depending on age, symptoms, weight, use and the like, and are not particularly limited. For example, one or more amino acids (in terms of solid content) selected from glutamine, methionine and phenylalanine, with lower limit values of 0.2 g, 0.3 g, 0.4 g, 0.5 g, 0.6 g, Alternatively, there is an example of ingesting or administering with 0.9 g and an upper limit set to 5 g, 4 g, 3 g, 2.5 g, 2 g, or 1.5 g. More specifically, one or two selected from glutamine, methionine and phenylalanine for reducing gastric volume or for the prevention, treatment and / or amelioration of diseases and symptoms (particularly obesity) described below. The daily intake and dose of the above amino acids (in terms of solid content) in humans can be 0.2 to 5 g, preferably 0.3 to 4.0 g, and more preferably 0.7 to 2. It is 0 g, particularly preferably 0.9 to 1.5 g.
例えば、例２に示す飲料（アミノ酸含量：０．５ｗ／ｖ％）を４０ｍｌ、１００ｍｌ、２００ｍｌ、３００ｍｌ、５００ｍｌ、１０００ｍｌ摂取すると、本発明の剤のアミノ酸を０．２ｇ、０．５ｇ、１ｇ、１．５ｇ、２．５ｇ、５ｇ摂取したことになる。 For example, when 40 ml, 100 ml, 200 ml, 300 ml, 500 ml, and 1000 ml of the beverage (amino acid content: 0.5 w / v%) shown in Example 2 are ingested, the amino acids of the agent of the present invention are 0.2 g, 0.5 g, 1 g, and so on. It means that 1.5g, 2.5g and 5g were ingested.
例えば、例３に示すタブレット（アミノ酸含量：２００ｍｇ／錠、約３３ｗ／ｗ％）を１、２、３、５、１０、２０錠摂取すると、本発明の剤のアミノ酸を０．２ｇ、０．４ｇ、０．６ｇ、１ｇ、２ｇ、４ｇ摂取したことになる。 For example, when 1, 2, 3, 5, 10 and 20 tablets (amino acid content: 200 mg / tablet, about 33 w / w%) shown in Example 3 are ingested, 0.2 g of the amino acid of the agent of the present invention, 0. It means that 4g, 0.6g, 1g, 2g and 4g were ingested.
例えば、例４に示すサプリメント（アミノ酸含量：３００ｍｇ／粒）を１、２、３、５、１０粒摂取すると、本発明の剤のアミノ酸を０．３ｇ、０．６ｇ、０．９ｇ、１．５ｇ、３ｇ摂取したことになる。 For example, when the supplement shown in Example 4 (amino acid content: 300 mg / grain) is ingested 1, 2, 3, 5, 10 grains, the amino acids of the agent of the present invention are 0.3 g, 0.6 g, 0.9 g, 1. It means that 5g and 3g were ingested.
また、例４に示すサプリメントの類型として、本発明の剤のアミノ酸３００ｍｇを０．０８ｇの１号カプセルに充填してサプリメントを製造した場合、サプリメント中の本発明の剤のアミノ酸含量は、約７９ｗ／ｗ％となる。 In addition, as a type of supplement shown in Example 4, when a supplement is produced by filling 300 mg of the amino acid of the agent of the present invention in a No. 1 capsule of 0.08 g, the amino acid content of the agent of the present invention in the supplement is about 79 w. / W%.
なお、本発明の剤は、従来公知の胃容量の減少効果がある組成物、飲食品、または医薬品などの摂取と同時または、それらの摂取の前後に併用してもよいし、胃容量の減少処置（減肥手術、バルーン留置など）などと同時または、それらの処置の前後に併用してもよい。具体的には、満腹中枢刺激剤、食物繊維、減肥手術、バルーン留置などが挙げられるが、これらの例に限定されない。 The agent of the present invention may be used at the same time as or before or after ingestion of a conventionally known composition, food or drink, drug or the like having a gastric volume reducing effect, or may be used in combination before or after the ingestion of the composition, food or drink, pharmaceuticals, etc. It may be used at the same time as treatments (bariatric surgery, balloon placement, etc.) or before and after those treatments. Specific examples include, but are not limited to, satiety central stimulants, dietary fiber, bariatric surgery, balloon placement and the like.
本発明の剤は、各種の飲食品（牛乳、清涼飲料、加工乳、乳性飲料、発酵乳、乳酸菌飲料、ヨーグルト、チーズ、パン、ビスケット、クラッカー、ピッツァクラスト、グミ、飴、焼き菓子、プリン、ゼリー、ババロア、調製粉乳、流動食、病者用食品、栄養食品、冷凍食品、加工食品その他の市販食品など）に配合して、これを摂取してもよい。これらの飲食品の形態として、液状、ペースト状、ゲル状、固形状、粉末状などを問わない。また、各種の飲食品に通常より明らかに高濃度のグルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を配合し、これを摂取するものであってもよい。 The agent of the present invention includes various foods and drinks (milk, soft drinks, processed milk, dairy drinks, fermented milk, lactic acid bacteria drinks, yogurt, cheese, bread, biscuits, crackers, pizza crusts, gummy, candy, baked goods, puddings. , Jelly, Bavaroa, milk powder, liquid foods, foods for the sick, nutritional foods, frozen foods, processed foods and other commercial foods) may be mixed and ingested. The form of these foods and drinks may be liquid, paste, gel, solid, powder or the like. In addition, various foods and drinks may be ingested by blending one or more selected from glutamine, methionine and phenylalanine, which are clearly higher in concentration than usual.
本発明の剤を配合する飲食品の成分には、水、タンパク質、ペプチド、アミノ酸、糖質、脂質、ビタミン類、ミネラル類、有機酸、有機塩基、果汁、フレーバー類等を用いることができるが、これらには特に限定されない。タンパク質として、例えば、全脂粉乳、脱脂粉乳、部分脱脂粉乳、カゼイン、ホエイ粉、ホエイタンパク質、ホエイタンパク質濃縮物、ホエイタンパク質分離物、ホエイタンパク質加水分解物、α−カゼイン、β−カゼイン、κ−カゼイン、β−ラクトグロブリン、α−ラクトアルブミン、ラクトフェリン、大豆タンパク質、鶏卵タンパク質、肉タンパク質等の動植物性タンパク質、これらの分解物、ホエイ、非タンパク態窒素等が挙げられる。また、ペプチドとして、例えば、カゼインホスホペプチド等が挙げられる。 Water, proteins, peptides, amino acids, sugars, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like can be used as components of foods and drinks containing the agents of the present invention. , These are not particularly limited. Examples of proteins include full fat powder, defatted milk powder, partially defatted milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, whey protein hydrolyzate, α-casein, β-casein, κ- Examples include animal and vegetable proteins such as casein, β-lactoglobulin, α-lactoalbumin, lactoferrin, soybean protein, chicken egg protein, meat protein, decomposition products thereof, whey, non-protein nitrogen and the like. Further, examples of the peptide include casein phosphopeptide and the like.
また、糖質として、例えば、糖類、加工澱粉（テキストリンのほか、可溶性澱粉、ブリティッシュスターチ、酸化澱粉、澱粉エステル、澱粉エーテル等）、食物繊維等が挙げられる。また、脂質として、例えば、ラード、魚油、エステル交換油等の動物性油脂、パーム油、サフラワー油、コーン油、ナタネ油、ヤシ油等、これらの分別油、水素添加油、エステル交換油等の植物性油脂等が挙げられる。また、ビタミン類として、例えば、ビタミンＡ、カロチン類、ビタミンＢ群、ビタミンＣ、ビタミンＤ群、ビタミンＥ、ビタミンＫ群、ビタミンＰ、ビタミンＱ、ナイアシン、ニコチン酸、パントテン酸、ビオチン、イノシトール、コリン、葉酸等が挙げられる。 Examples of carbohydrates include sugars, modified starches (in addition to textrin, soluble starches, British starch, oxidized starches, starch esters, starch ethers, etc.), dietary fiber and the like. Further, as lipids, for example, animal fats and oils such as lard, fish oil and ester exchange oil, palm oil, safflower oil, corn oil, rapeseed oil, coconut oil and the like, these fractionated oils, hydrogenated oils, ester exchange oils and the like. Examples include vegetable oils and fats. In addition, as vitamins, for example, vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, etc. Examples include choline and folic acid.
また、ミネラル類として、例えば、カルシウム、カリウム、マグネシウム、ナトリウム、銅、鉄、マンガン、亜鉛、セレン等が挙げられる。また、有機酸として、例えば、リンゴ酸、クエン酸、乳酸、酒石酸、エリソルビン酸等が挙げられる。なお、これらの飲食品の成分は、単独で、または複数種類を組み合わせて用いることがでる。また、合成品および／または天然物であってもよい。これらの飲食品の成分の形態として、液状、ペースト状、ゲル状、固形状、粉末状などのいずれであってもよい。 In addition, examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and the like. Further, examples of the organic acid include malic acid, citric acid, lactic acid, tartaric acid, erythorbic acid and the like. The components of these foods and drinks can be used alone or in combination of two or more. It may also be a synthetic product and / or a natural product. The form of the components of these foods and drinks may be liquid, paste, gel, solid, powder or the like.
本発明の剤では、特定保健用食品等の保健機能食品、特別用途食品、栄養機能食品、栄養補助食品、病者用食品、健康補助食品、機能性食品、医薬部外品または医薬品等の製品として提供して、あるいはそれら製品に配合して、対象に投与することできる。特に、本発明の剤では、特定保健用食品等の保健機能食品、特別用途食品、栄養機能食品、栄養補助食品、病者用食品、健康補助食品または機能性食品として提供することは、消費者に対して一般（飲）食品との区別を明確にしながら、胃容量を減少させる上で有利である。 The agent of the present invention includes products such as health functional foods such as foods for specified health use, special purpose foods, nutritional functional foods, nutritional supplements, foods for the sick, health supplements, functional foods, non-pharmaceutical products or pharmaceuticals. Can be administered to a subject as provided as, or in combination with those products. In particular, the agent of the present invention may be provided as a health functional food such as a food for specified health use, a special purpose food, a nutritional functional food, a nutritional supplement, a food for the sick, a health supplement or a functional food. On the other hand, it is advantageous in reducing gastric capacity while clarifying the distinction from general (drinking) foods.
本発明において、上記に挙げた食品、特定保健用食品、保健機能食品、特別用途食品、栄養機能食品、栄養補助食品、病者用食品、健康補助食品、機能性食品、サプリメント、本発明の剤および製剤化のための補助剤のみからなる剤、医薬部外品、または医薬品の、１包装単位に含まれるグルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上の量は、グルタミン、メチオニンおよびフェニルアラニンの固形分換算で０．２ｇ、０．３ｇ、０．４ｇ、０．６ｇ、０．７ｇ、０．８ｇ、０．９ｇ、または１ｇ、１．５ｇに設定することができる。 In the present invention, the foods listed above, foods for specified health use, foods with health claims, foods for special use, foods with nutritional claims, dietary supplements, foods for the sick, health supplements, functional foods, supplements, agents of the present invention. And one or more selected from glutamine, methionine and phenylalanine contained in one packaging unit of an agent consisting only of supplements for formulation, non-pharmaceutical products, or pharmaceuticals, glutamine, methionine. And can be set to 0.2 g, 0.3 g, 0.4 g, 0.6 g, 0.7 g, 0.8 g, 0.9 g, or 1 g, 1.5 g in terms of solid content of phenylalanine.
本発明の剤は、健常者はもとより、肥満、糖尿病、高脂血症、過食症、多食症等の節食が必要な症状を有する者において、飲食の前、飲食と同時、または飲食の後に摂取することで、これらの疾患や症状を予防、治療および／または改善することができる。あるいは、他の節食が必要な疾患や身体の不調（肥満など）を有する者が、本発明の剤を摂取することで、これらの疾患や症状を予防、治療および／または改善することができる。特に、本発明の剤は、胃排出を促進せずに、胃容量を減少させることができ、また、背景技術の欄に記載したように肥満の治療法（減量）として胃容量を減少させることが非常に有効であることから、本発明の剤は肥満を効率的に予防、治療および／または改善することができる。 The agent of the present invention can be used not only in healthy subjects but also in persons with obesity, diabetes, hyperlipidemia, bulimia nervosa, polyphagia and other symptoms requiring dietary reduction before, at the same time as, or after eating or drinking. Ingestion can prevent, treat and / or ameliorate these diseases and symptoms. Alternatively, a person having another diet-saving disease or physical disorder (such as obesity) can prevent, treat and / or ameliorate these diseases and symptoms by taking the agent of the present invention. In particular, the agent of the present invention can reduce gastric volume without promoting gastric emptying, and as described in the background art column, it can reduce gastric volume as a treatment method (weight loss) for obesity. Is so effective that the agents of the present invention can efficiently prevent, treat and / or ameliorate obesity.
本発明は、胃容量の減少剤を製造するための、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上の使用（使用方法）、でもある。また、本発明は、肥満の予防、治療および／または改善剤を製造するための、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上の使用（使用方法）、でもある。 The present invention is also the use (method of use) of one or more selected from glutamine, methionine and phenylalanine for producing a gastric volume reducing agent. The present invention is also the use (method of use) of one or more selected from glutamine, methionine and phenylalanine for the production of obesity prevention, treatment and / or ameliorating agents.
本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を経口摂取に用いることを特徴とする、胃容量を減少させる方法、でもある。また、本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を経口摂取あるいは経口投与に用いることを特徴とする、肥満を予防、治療および／または改善する方法、でもある。上記二つの方法においては、ヒトに対する医療行為が除かれていてもよい。 The present invention is also a method for reducing gastric volume, which comprises using one or more selected from glutamine, methionine and phenylalanine for oral ingestion. The present invention is also a method for preventing, treating and / or ameliorating obesity, which comprises using one or more selected from glutamine, methionine and phenylalanine for oral ingestion or oral administration. In the above two methods, medical practice for humans may be excluded.
本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を（商業的に提供して）経口摂取させることを特徴とする、胃容量を減少させる方法、でもある。また、本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を（商業的に提供して）経口摂取させることを特徴とする、肥満を予防、治療および／または改善する方法、でもある。上記二つの方法においては、ヒトに対する医療行為が除かれていてもよい。 The present invention is also a method of reducing gastric volume, characterized in that one or more selected from glutamine, methionine and phenylalanine are orally ingested (commercially provided). The present invention also comprises orally ingesting one or more selected from glutamine, methionine and phenylalanine (commercially provided), a method for preventing, treating and / or ameliorating obesity. , But also. In the above two methods, medical practice for humans may be excluded.
本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有する、胃容量の減少用の組成物でもある。また、本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有する、肥満の予防、治療および／または改善用の組成物でもある。 The present invention is also a composition for reducing gastric volume, which contains one or more selected from glutamine, methionine and phenylalanine as an active ingredient. The present invention is also a composition for preventing, treating and / or ameliorating obesity, which contains one or more selected from glutamine, methionine and phenylalanine as an active ingredient.
本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有し、食品衛生上許容可能な他の添加成分を含有する、胃容量の減少用の飲料やドリンク剤でもある。また、本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有し、食品衛生上許容可能な他の添加成分を含有する、肥満の予防、治療および／または改善用の飲料やドリンク剤でもある。上記飲料およびドリンク剤に使用できる食品衛生上許容可能な他の添加成分としては、甘味料、酸味料などの食品添加物が挙げられる。 The present invention is a beverage or drink for reducing gastric volume, which comprises one or more selected from glutamine, methionine and phenylalanine as an active ingredient and contains other additive ingredients acceptable for food hygiene. But also. In addition, the present invention contains one or more selected from glutamine, methionine and phenylalanine as an active ingredient, and contains other additive ingredients acceptable for food hygiene, for the prevention, treatment and / or of obesity. It is also a beverage and drink for improvement. Other food hygiene-acceptable additive components that can be used in the beverages and drinks include food additives such as sweeteners and acidulants.
本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有し、食品衛生上許容可能な他の添加成分を含有し、製剤化補助剤を含有する、胃容量の減少用の錠剤（タブレット）などのサプリメントでもある。また、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有し、食品衛生上許容可能な他の添加成分を含有し、製剤化補助剤を含有する、肥満の予防、治療および／または改善用の錠剤（タブレット）などのサプリメントでもある。上記サプリメントに使用できる食品衛生上許容可能な他の添加成分としては、甘味料、酸味料、乳化剤、香料などの食品添加物が挙げられる。上記サプリメントに使用できる製剤化補助剤としては、賦形剤、結合剤、崩壊剤、滑沢剤の何れか１種又は２種以上が挙げられる。 The present invention contains one or more selected from glutamine, methionine and phenylalanine as an active ingredient, contains other additive ingredients acceptable for food hygiene, and contains a formulation aid, gastric volume. It is also a supplement such as tablets for reducing methionine. In addition, obesity prevention, which contains one or more selected from glutamine, methionine and phenylalanine as an active ingredient, contains other additive ingredients acceptable for food hygiene, and contains a formulation aid. It is also a supplement such as a tablet for treatment and / or improvement. Other food hygiene-acceptable additives that can be used in the supplements include food additives such as sweeteners, acidulants, emulsifiers, and flavors. Examples of formulation aids that can be used in the above supplements include any one or more of excipients, binders, disintegrants, and lubricants.
本発明は、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有し、製剤化補助剤を含有する、胃容量の減少用のカプセルなどのサプリメントでもある。また、グルタミン、メチオニンおよびフェニルアラニンから選択される１種または２種以上を有効成分として含有し、製剤化補助剤を含有する、肥満の予防、治療および／または改善用のカプセルなどのサプリメントでもある。上記サプリメントに使用できる製剤化補助剤としては、賦形剤、結合剤、崩壊剤、滑沢剤の何れか１種又は２種以上が挙げられる。 The present invention is also a supplement such as a capsule for reducing gastric volume, which contains one or more selected from glutamine, methionine and phenylalanine as an active ingredient and contains a formulation aid. It is also a supplement such as a capsule for the prevention, treatment and / or amelioration of obesity, which contains one or more selected from glutamine, methionine and phenylalanine as an active ingredient and contains a formulation aid. Examples of formulation aids that can be used in the above supplements include any one or more of excipients, binders, disintegrants, and lubricants.
本発明の好ましい態様によれば、
グルタミン、メチオニンおよびフェニルアラニンからなる群から選択される１種または２種以上のアミノ酸を有効成分として含有する、胃の伸展刺激に適応した胃底部および／または胃体上部の弛緩抑制剤、
グルタミン、メチオニンおよびフェニルアラニンからなる群から選択される１種または２種以上のアミノ酸を摂取させることを含んでなる、胃の伸展刺激に適応した胃底部および／または胃体上部の弛緩を抑制する方法、および
胃の伸展刺激に適応した胃底部および／または胃体上部の弛緩抑制剤の製造のための、グルタミン、メチオニンおよびフェニルアラニンからなる群から選択される１種または２種以上のアミノ酸の使用
が提供される。上記発明は本発明の胃容量減少剤および各種疾患や症状の予防、治療および／または改善剤並びに本発明の剤のアミノ酸に関する記載に従って実施することができる。According to a preferred embodiment of the present invention
A fundus and / or upper body relaxation inhibitor adapted for gastric extension stimulation, which contains one or more amino acids selected from the group consisting of glutamine, methionine and phenylalanine as active ingredients.
Suppresses relaxation of the bottom and / or upper body of the stomach adapted to gastric extension stimulation, which involves ingesting one or more amino acids selected from the group consisting of glutamine, methionine and phenylalanine. Of one or more amino acids selected from the group consisting of glutamine, methionine and phenylalanine for the method and the production of anti-relaxation agents in the bottom and / or body of the stomach adapted to the stimulation of gastric extension. Use is provided. The above invention can be carried out in accordance with the description of the gastric volume reducing agent of the present invention, the prophylactic, therapeutic and / or ameliorating agent of various diseases and symptoms, and the amino acids of the agent of the present invention.
本発明によれば下記発明が提供される。
［２１］グルタミン、メチオニン、フェニルアラニンから選択される１種または２種以上を有効成分として含有する、胃容量の減少剤。
［２２］胃の伸展刺激に適応した胃底部および／または胃体上部の弛緩を抑制することを特徴とする、上記［２１］に記載の剤。
［２３］胃排出を促進しないことを特徴とする、上記［２１］または［２２］に記載の剤。
［２４］ヒトの１日当たりの摂取量が０．２〜５ｇである、上記［２１］〜［２３］のいずれかに記載の剤。
［２５］上記［２１］〜［２３］のいずれかに記載の剤を有効成分とする、肥満の予防および／または改善剤。
［２６］グルタミン、メチオニン、フェニルアラニンから選択される１種または２種以上を経口摂取に用いることを特徴とする、胃容量を減少させる方法（ヒトに対する医療行為を除く）。
［２７］グルタミン、メチオニン、フェニルアラニンから選択される１種または２種以上を経口摂取させることを特徴とする、胃容量を減少させる方法（ヒトに対する医療行為を除く）。According to the present invention, the following invention is provided.
[21] An agent for reducing gastric volume, which contains one or more selected from glutamine, methionine, and phenylalanine as an active ingredient.
[22] The agent according to the above [21], which suppresses relaxation of the bottom of the stomach and / or the upper part of the gastric body adapted to the stimulation of gastric extension.
[23] The agent according to the above [21] or [22], which does not promote gastric emptying.
[24] The agent according to any one of the above [21] to [23], wherein the daily intake of a human is 0.2 to 5 g.
[25] An obesity-preventing and / or ameliorating agent containing the agent according to any one of the above [21] to [23] as an active ingredient.
[26] A method for reducing gastric volume (excluding medical practice for humans), which comprises using one or more selected from glutamine, methionine, and phenylalanine for oral ingestion.
[27] A method for reducing gastric volume (excluding medical practice for humans), which comprises ingesting one or more selected from glutamine, methionine, and phenylalanine.
以下、本発明に関して、例を挙げて説明するが、本発明は、これにより限定されるものではない。 Hereinafter, the present invention will be described with reference to examples, but the present invention is not limited thereto.
例１：各種アミノ酸における、胃容量の減少効果の試験
（１）材料および方法
［被検試料］
１９種類のアミノ酸（Ｌ−Ｐｈｅｎｙｌ ａｌａｎｉｎｅ（Ｐｈｅ）、Ｌ−Ｌｙｓｉｎｅ（Ｌｙｓ）、Ｇｌｙｃｉｎｅ（Ｇｌｙ）、Ｌ−Ｃｙｓｔｅｉｎｅ（Ｃｙｓ）、Ｌ−Ｓｅｒｉｎｅ（Ｓｅｒ）、Ｌ−Ａｌａｎｉｎｅ、Ｌ−Ｐｒｏｌｉｎｅ（Ｐｒｏ）、Ｌ−Ａｒｇｉｎｉｎｅ（Ａｒｇ）、Ｌ−Ｈｉｓｔｉｄｉｎｅ（Ｈｉｓ）、Ｌ−Ｔｈｒｅｏｎｉｎｅ、Ｌ−Ｖａｌｉｎｅ、Ｌ−Ｇｌｕｔａｍｉｎｅ、Ｌ−Ａｓｐａｒａｇｉｎｅ（Ａｓｎ）、Ｌ−Ｍｅｔｈｉｏｎｉｎｅ、Ｌ−Ｇｌｕｔａｍｉｃ ａｃｉｄ、Ｌ−Ａｓｐａｒｔｉｃ ａｃｉｄ（Ａｓｐ）、Ｌ−Ｉｓｏｌｅｕｃｉｎｅ、Ｌ−Ｌｅｕｃｉｎｅ、およびＬ−Ｔｙｒｏｓｉｎｅ）を被検試料として用いた。 Example 1: Test of gastric volume reduction effect on various amino acids (1) Materials and methods [Test sample]
19 kinds of amino acids (L-Phenyl alane (Phe), L-Lycine (Lys), Glycine (Gly), L-Cysteine (Cys), L-Serine (Ser), L-Alanine, L-Proline (Pro), L-Arginine (Arg), L-Histidine (His), L-Threone, L-Valine, L-Glutamine, L-Aspargine (Asn), L-Mestionine, L-Glutamic acid, L-Aspartic L-Isoleucine, L-Leucine, and L-Tyrosine) were used as test samples.
前記のアミノ酸のうち、Ｌｙｓには、塩酸塩、Ａｓｎには、一水和物、他のアミノ酸には、ｆｒｅｅ ｂａｓｅ を用いた。これらアミノ酸を、各々１ｇ／５ｍｌの濃度で注射用水（大塚製薬）に溶解・懸濁して用いた。 Among the above amino acids, hydrochloride was used for Lys, monohydrate was used for Asn, and free base was used for other amino acids. Each of these amino acids was dissolved and suspended in water for injection (Otsuka Pharmaceutical Co., Ltd.) at a concentration of 1 g / 5 ml.
［陽性対照試料］
陽性対照として、胃もたれの改善に用いられる漢方薬である、六君子湯（ツムラ六君子湯エキス顆粒(医療用)、ツムラ）を５００ｍｇ／５ｍｌの濃度で注射用水（大塚製薬）に溶解・懸濁して用いた。
［バロスタットバッグ］
ポリエチレン製の袋（最大容量：７ｍｌ、最大直径：３ｃｍ）にポリビニル製のチューブの２本を接続したバロスタットバッグを用いた。[Positive control sample]
As a positive control, Rikkunshito (Tsumura Rikkunshito extract granules (medical use), Tsumura), which is a Chinese herbal medicine used to improve stomach upset, was dissolved and suspended in water for injection (Otsuka Pharmaceutical) at a concentration of 500 mg / 5 ml. Used.
[Barostat bag]
A barostat bag in which two polyvinyl tubes were connected to a polyethylene bag (maximum capacity: 7 ml, maximum diameter: 3 cm) was used.
［動物実験］
内田らの論文（Ｍａｓａｙｕｋｉ ＵＣＨＩＤＡ、Ｋｉｍｉｋｏ ＳＨＩＭＩＺＵ、「Ｍｅｔｈｏｄ ｔｏ ｅｖａｌｕａｔｅ ａｄａｐｔｉｖｅ ｒｅｌａｘａｔｉｏｎ ｏｆ ｔｈｅ ｓｔｏｍａｃｈ ｂｙ ｕｓｉｎｇ Ｂａｒｏｓｔａｔ ｉｎ ｒａｔｓ ｗｉｔｈｏｕｔ ｓｕｒｇｉｃａｌ ｏｐｅｒａｔｉｏｎ，ａｎｄ ｔｈｅ ｅｆｆｅｃｔｓ ｏｆ ｃａｐｓａｉｃｉｎ ａｎｄ Ｎω−ｎｉｔｒｏ−Ｌ−ａｒｇｉｎｉｎｅ−ｍｅｔｈｙｌｅｓｔｅｒ ｏｎ ａｄａｐｔｉｖｅ ｒｅｌａｘａｔｉｏｎ．」、Ｊ．Ｓｍｏｏｔｈ Ｍｕｓｃｌｅ Ｒｅｓ．、（２０１２）４８（４））を参考に行った。[Animal experimentation]
Uchida et al (Masayuki UCHIDA, Kimiko SHIMIZU, "Method to evaluate adaptive relaxation of the stomach by using Barostat in rats without surgical operation, and the effects of capsaicin and Nω-nitro-L-arginine-methylester on adaptive relaxation." J. Smooth Muscle Res., (2012) 48 (4)) was referred to.
すなわち、８週齢のＳＤ系雄性ラット（ＳＬＣ社）を１週間で予備飼育して試験に用いた。試験開始日の前日に、体重に基づいて群分けし（全２０群、各ｎ＝４〜８匹）、１８〜２０時間で絶食した（ただし、水を自由摂取とした）。
被検試料投与群に、前記の各種アミノ酸の溶解・懸濁液を５ｍｌ／ｋｇ（被検試料の用量１ｇ／ｋｇ）、Ｃｏｎｔｒｏｌ群に、注射用水を５ｍｌ／ｋｇ、陽性対照群に、六君子湯の溶解・懸濁液を５ｍｌ／ｋｇ（六君子湯の用量 ５００ｍｇ／ｋｇ）で強制的に経口摂取させた。That is, 8-week-old male SD rats (SLC) were preliminarily bred for 1 week and used for the test. On the day before the test start date, the animals were grouped based on body weight (20 groups in total, n = 4 to 8 animals each) and fasted for 18 to 20 hours (however, water was taken freely).
In the test sample administration group, 5 ml / kg of the above-mentioned dissolution / suspension of various amino acids (dose of the test sample: 1 g / kg), in the Control group, 5 ml / kg of water for injection, in the positive control group, Rikkunshito The solution / suspension of hot water was forcibly ingested at 5 ml / kg (Rikkunshito dose 500 mg / kg).
被検試料または注射用水の投与２０分後に、ウレタンにて麻酔（２０％ウレタン、６ｍｌ／ｋｇ、腹腔内投与）を行い、被検試料または注射用水の投与２５分後に、バロスタットバッグを経口より胃内に挿入した。一方のチューブを閉じた状態で、もう一方のチューブから空気７ｍｌをバロスタットバッグに注入し、バロスタットバッグが胃底部〜胃体上部に位置するように調整した。その後、速やかにバロスタットバッグの空気を抜いた。 20 minutes after administration of the test sample or water for injection, anesthesia with urethane (20% urethane, 6 ml / kg, intraperitoneal administration) is performed, and 25 minutes after administration of the test sample or water for injection, a barostat bag is orally administered. It was inserted into the stomach. With one tube closed, 7 ml of air was injected into the barostat bag from the other tube, and the barostat bag was adjusted to be located from the fundus to the upper body of the stomach. After that, the barostat bag was promptly deflated.
被検試料または注射用水の投与３０分後に、バロスタット装置（Ｂａｒｏｓｔａｔ Ｄｉｓｔｅｎｄｅｒ ＩＩＲ、Ｇ＆Ｊ Ｅｌｅｃｔｒｏｎｉｃｓ）に接続して、呼吸を保持しつつ、バロスタットバッグを膨らませて、バロスタットバッグの内圧および容量を測定した。具体的には、バロスタットバッグの内圧を初期値で０ｍｍＨｇとし、段階的に内圧を増加させて、胃底部〜胃体上部に伸展刺激を与えた。 Thirty minutes after administration of the test sample or water for injection, the barostat bag was inflated and the internal pressure and volume of the barostat bag were measured by connecting to a barostat device (Barostat Disaster IIR, G & J Electronics) and holding breathing. .. Specifically, the internal pressure of the barostat bag was set to 0 mmHg at the initial value, and the internal pressure was gradually increased to stimulate the extension from the fundus to the upper body of the stomach.
測定開始後０〜１分、１〜２分、２〜３分、３〜４分におけるバロスタットバッグの内圧を、１ｍｍＨｇ、２ｍｍＨｇ、４ｍｍＨｇ、８ｍｍＨｇに設定して、継続的にバロスタットバッグの容量を測定した（図１）。 The internal pressure of the barostat bag at 0 to 1 minute, 1 to 2 minutes, 2 to 3 minutes, and 3 to 4 minutes after the start of measurement is set to 1 mmHg, 2 mmHg, 4 mmHg, and 8 mmHg, and the capacity of the barostat bag is continuously set. Was measured (Fig. 1).
測定終了後に、バロスタットバッグを膨らしたままで腹部を切開し、胃部を観察して、バロスタットバッグの挿入具合（位置など）、バロスタットバッグの膨らみ具合、出血の有無等を確認した。 After the measurement was completed, the abdomen was incised with the barostat bag inflated, and the stomach was observed to check the insertion condition (position, etc.) of the barostat bag, the bulging condition of the barostat bag, and the presence or absence of bleeding. ..
［評価］
各段階のバロスタットバッグの内圧を約１分間で維持する間に増加したバロスタットバッグの容量（ｍｌ）を算出し、これをＡｄａｐｔｉｖｅ ｒｅｌａｘａｔｉｏｎ（ｍｌ）とした（図１）。さらに、各内圧で得られた値をｃｏｎｔｒｏｌ群の値で除して、適応弛緩（％対コントロール群）を算出した。[Evaluation]
The volume (ml) of the barostat bag increased while maintaining the internal pressure of the barostat bag at each stage in about 1 minute was calculated, and this was taken as Adaptive relaxation (ml) (FIG. 1). Furthermore, the value obtained at each internal pressure was divided by the value of the control group to calculate adaptive relaxation (% vs. control group).
（２）結果
図２にバロスタットバックの内圧が８ｍｍＨｇのときの、適応弛緩（Ａｄａｐｔｉｖｅ ｒｅｌａｘａｔｉｏｎ）を示す。Ｇｌｎ群、Ｍｅｔ群では、いずれも、Ｃｏｎｔｒｏｌ群より有意に低い値を示した。また、Ｐｈｅ群では、胃底部〜胃体上部の収縮作用が強く起こり、バロスタットバッグが胃底部〜胃体上部から押し出されて胃体部に移動した。この現象では、Ｐｈｅは、ＧｌｎやＭｅｔよりもさらに強い作用を有することを示している。(2) Results Fig. 2 shows the adaptive relaxation when the internal pressure of the barostat back is 8 mmHg. In both the Gln group and the Met group, the values were significantly lower than those in the Control group. In the Ph group, the contraction action from the fundus to the upper body of the stomach strongly occurred, and the barostat bag was pushed out from the fundus to the upper body of the stomach and moved to the body of the stomach. In this phenomenon, Ph has been shown to have a stronger effect than Gln and Met.
このことから、Ｇｌｎ、Ｍｅｔ、Ｐｈｅは、胃の伸展刺激に適応した胃底部および／または胃体上部の弛緩を抑制し、可逆的に胃容量を減少させることがわかった。 From this, it was found that Gln, Met, and Phe suppress the relaxation of the fundus and / or the upper body of the stomach adapted to the stimulation of gastric extension, and reversibly reduce the gastric volume.
例２：本発明の剤を配合した飲料の製造方法
Ｌ−グルタミンを０．５ｗ／ｖ％、甘味料１．０ｗ／ｖ％、酸味料０．９ｗ／ｖ％、および増粘剤０．２ｗ／ｖ％の濃度で配合し、常法に従って飲料を製造した。この飲料を４０ｍｌ、１００ｍｌ、２００ｍｌ、３００ｍｌ、５００ｍｌ、１０００ｍｌを摂取すると、Ｌ−グルタミンを０．２ｇ、０．５ｇ、１ｇ、１．５ｇ、２．５ｇ、５ｇ摂取することができる。 Example 2: Method for producing a beverage containing the agent of the present invention L-glutamine is 0.5 w / v%, sweetener 1.0 w / v%, acidulant 0.9 w / v%, and thickener 0.2 w. Beverages were prepared according to conventional methods by blending at a concentration of / v%. When 40 ml, 100 ml, 200 ml, 300 ml, 500 ml, and 1000 ml of this beverage are ingested, 0.2 g, 0.5 g, 1 g, 1.5 g, 2.5 g, and 5 g of L-glutamine can be ingested.
同様にして、Ｌ−メチオニンを０．５ｗ／ｖ％配合した飲料、Ｌ−フェニルアラニンを０．５ｗ／ｖ％配合した飲料、Ｌ−グルタミン０．２ｗ／ｖ％とＬ−メチオニン０．１ｗ／ｖ％とＬ−フェニルアラニン０．２ｗ／ｖ％を配合した飲料、および、Ｌ−グルタミン０．１ｗ／ｖ％とＬ−フェニルアラニン０．４ｗ／ｖ％を配合した飲料を製造した。 Similarly, a beverage containing 0.5 w / v% of L-methionine, a beverage containing 0.5 w / v% of L-phenylalanine, 0.2 w / v% of L-glutamine and 0.1 w / v of L-methionine. A beverage containing 0.2 w / v% of L-phenylalanine and a beverage containing 0.1 w / v% of L-glutamine and 0.4 w / v% of L-phenylalanine were produced.
例３：本発明の剤を配合したタブレットの製造方法
Ｌ−グルタミン２００ｍｇに賦形剤、結合剤、崩壊剤、滑沢剤、酸味料、乳化剤、香料、および甘味料などを配合し、常法に従って約６００ｍｇのタブレットを製造した（Ｌ−アスパラギン酸含量：約３３ｗ／ｗ％）。このタブレット１、２、３、５、１０、２０錠を摂取すると、Ｌ−グルタミンを０．２ｇ、０．４ｇ、０．６ｇ、１ｇ、２ｇ、４ｇ摂取することができる。 Example 3: Method for producing a tablet containing the agent of the present invention A conventional method in which 200 mg of L-glutamine is mixed with an excipient, a binder, a disintegrant, a lubricant, an acidulant, an emulsifier, a fragrance, and a sweetener. According to this, about 600 mg of tablets were produced (L-aspartic acid content: about 33 w / w%). When these
同様にして、Ｌ−メチオニンを２００ｍｇ配合したタブレット、Ｌ−フェニルアラニンを２００ｍｇ配合したタブレット、Ｌ−グルタミン５０ｍｇとＬ−メチオニン５０ｍｇとＬ−フェニルアラニン１００ｍｇを配合したタブレット、および、Ｌ−メチオニン１００ｍｇとＬ−フェニルアラニン１００ｍｇを配合したタブレット製造した。 Similarly, a tablet containing 200 mg of L-methionine, a tablet containing 200 mg of L-phenylalanine, a tablet containing 50 mg of L-glutamine, 50 mg of L-methionine and 100 mg of L-phenylalanine, and 100 mg of L-methionine and L- A tablet containing 100 mg of phenylalanine was produced.
例４：本発明の剤を配合したサプリメントの製造方法
Ｌ−グルタミン３００ｍｇに賦形剤などを添加して、カプセルに充填してサプリメントを製造した。このサプリメント１、２、３、５、１０粒摂取すると、Ｌ−グルタミンを０．３ｇ、０．６ｇ、０．９ｇ、１．５ｇ、３ｇ摂取することができる。 Example 4: Method for producing a supplement containing the agent of the present invention An excipient or the like was added to 300 mg of L-glutamine and filled into capsules to produce a supplement. By ingesting 1, 2, 3, 5, and 10 tablets of this supplement, 0.3 g, 0.6 g, 0.9 g, 1.5 g, and 3 g of L-glutamine can be ingested.
同様にして、Ｌ−メチオニンを３００ｍｇ充填したサプリメント、Ｌ−フェニルアラニンを３００ｍｇ充填したサプリメント、Ｌ−グルタミン５０ｍｇとＬ−メチオニン１００ｍｇとＬ−フェニルアラニン１５０ｍｇを充填したサプリメント、および、Ｌ−グルタミン２００ｍｇとＬ−メチオニン１００ｍｇを充填したサプリメントを製造した。 Similarly, a supplement filled with 300 mg of L-methionine, a supplement filled with 300 mg of L-phenylalanine, a supplement filled with 50 mg of L-glutamine, 100 mg of L-methionine and 150 mg of L-phenylalanine, and 200 mg of L-glutamine and L- A supplement filled with 100 mg of methionine was produced.
Claims (6)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015050583 | 2015-03-13 | ||
| JP2015050583 | 2015-03-13 | ||
| PCT/JP2016/057714 WO2016148046A1 (en) | 2015-03-13 | 2016-03-11 | Gastric volume-reducing agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2016148046A1 JPWO2016148046A1 (en) | 2017-12-28 |
| JP6764856B2 true JP6764856B2 (en) | 2020-10-07 |
Family
ID=56918686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506513A Active JP6764856B2 (en) | 2015-03-13 | 2016-03-11 | Stomach volume reducer |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6764856B2 (en) |
| TW (1) | TW201639555A (en) |
| WO (1) | WO2016148046A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833128A (en) * | 1984-12-28 | 1989-05-23 | Neil Solomon | Dietary supplement |
| JP5121308B2 (en) * | 2007-05-28 | 2013-01-16 | ハウスウェルネスフーズ株式会社 | Composition for preventing, improving or treating metabolic syndrome |
-
2016
- 2016-03-11 WO PCT/JP2016/057714 patent/WO2016148046A1/en active Application Filing
- 2016-03-11 TW TW105107583A patent/TW201639555A/en unknown
- 2016-03-11 JP JP2017506513A patent/JP6764856B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2016148046A1 (en) | 2017-12-28 |
| WO2016148046A1 (en) | 2016-09-22 |
| TW201639555A (en) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101061860B (en) | Leucine-rich nutritional compositions | |
| RU2356247C2 (en) | Combinations and compositions containing fatty acids and amino acids, their application for prevention and delay of progressing or treatment of diabetes and diabetes associated diseases and conditions, method of weight reduction in mammal, kit | |
| AU2013392167B2 (en) | Muscle preservation in overweight or obese adult during weight loss program | |
| CN103997914A (en) | Dietary product intended for the prevention of cardio-metabolic risk | |
| TWI592153B (en) | Methods of promoting the healing of diabetic ulcers using beta-hydroxy-beta-methylbutyrate with arginine and glutamine | |
| US20160367529A1 (en) | Debility preventative | |
| JP2002020312A (en) | Food composition for promoting reduction in body fat and promoter for reduction in body fat | |
| US20190183827A1 (en) | Composition for improving muscular endurance | |
| JP6764856B2 (en) | Stomach volume reducer | |
| JP6851086B2 (en) | Compositions and Methods for Treating Malnutrition | |
| JP6450689B2 (en) | Preventive or ameliorating agent for early postprandial satiety or gastroesophageal reflux disease | |
| JP5938219B2 (en) | Food or medical agent for delayed gastric emptying | |
| CN111655250A (en) | Composition for preventing or improving nociceptive pain | |
| WO2018123873A1 (en) | Composition for promoting perspiration | |
| JP6848962B2 (en) | Behavioral fitness improver | |
| WO2021112217A1 (en) | Composition for suppressing increase in amount of neutral fat in liver | |
| JP2019099498A (en) | Composition for promoting lipid metabolism | |
| US11938108B2 (en) | Composition for improving joint function | |
| JP2012180331A (en) | Oral ingestion medicine for inducement of early recovery of muscle damage | |
| US11045437B2 (en) | Composition for improving brain function | |
| JP5748441B2 (en) | Bone loss reducing agent containing citrulline as an active ingredient | |
| CA3216989A1 (en) | Nutritional compositions for preserving muscle mass | |
| JPWO2008047853A1 (en) | Preventive and therapeutic agent for gastroesophageal reflux disease | |
| JP2021087408A (en) | Composition for reducing amounts of enteric deoxycholic acid | |
| CA3234492A1 (en) | Dileucine compositions and methods of use thereof for fat loss |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200114 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200309 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200331 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200526 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200901 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200914 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6764856 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |